← Back to Search

Educational Video for Latent Tuberculosis

N/A
Waitlist Available
Research Sponsored by Kaiser Permanente
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Receipt of an LTBI treatment prescription order with specific medication ID codes for Isoniazid, Rifampin, Isoniazid + Rifampin, and Isoniazid + Rifapentine
Age ≥18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year after treatment prescription
Awards & highlights

Study Summary

This trial will test whether a 3-minute educational video can improve treatment completion rates for latent tuberculosis.

Who is the study for?
Adults who are members of Kaiser Permanente Southern California, diagnosed with latent tuberculosis (LTBI), and have been prescribed treatment. Participants must be at least 18 years old and not have an active TB diagnosis.Check my eligibility
What is being tested?
The trial is testing if a short educational video sent to patients via text or email can increase the completion rates of LTBI treatment compared to standard care without the video. Patients will be randomly assigned to either receive the video or continue with standard care.See study design
What are the potential side effects?
Since this intervention involves watching an educational video, there are no direct medical side effects associated with it. However, participants' perceptions and engagement with the video content will be evaluated.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been prescribed medication for latent TB infection.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year after treatment prescription
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year after treatment prescription for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment completion
Secondary outcome measures
Treatment completion by treatment regimen
Treatment initiation
Treatment initiation by treatment regimen
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: LTBI video interventionExperimental Treatment1 Intervention
Patients randomized to the intervention group will be sent an invitation with a link to watch a brief (~3 minute video) about the importance of taking and completing LTBI treatment.
Group II: Standard careActive Control1 Intervention
Patients who are randomized to receive standard of care will not receive any messages or have any contact with the research team.

Find a Location

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor
538 Previous Clinical Trials
24,111,886 Total Patients Enrolled

Media Library

LTBI video intervention Clinical Trial Eligibility Overview. Trial Name: NCT05412212 — N/A
Latent Tuberculosis Research Study Groups: Standard care, LTBI video intervention
Latent Tuberculosis Clinical Trial 2023: LTBI video intervention Highlights & Side Effects. Trial Name: NCT05412212 — N/A
LTBI video intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05412212 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining openings for participants in this research endeavor?

"Affirmative. According to the information accessible on clinicaltrials.gov, this medical trial is presently seeking candidates. It was initially posted on June 3rd 2022 and has since been refreshed as of June 16th 2022; 918 participants are needed from a single site for enrollment."

Answered by AI

What is the current cap for participants in this research project?

"Affirmative. Clinicaltrials.gov records indicate that this clinical trial, which was first uploaded on June 3rd 2022 is actively recruiting patients. A total of 918 individuals must be recruited from 1 medical centre for the study to commence."

Answered by AI
~507 spots leftby Dec 2024